# To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Study · id `cardio:ct-nct05908084` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05908084](<https://clinicaltrials.gov/study/NCT05908084>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05908084

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 121 participants.

## Technical summary

Registry record NCT05908084. Randomized; single masking; primary purpose treatment. Start 2023-09-07 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 121 participants (enrolled count; ClinicalTrials.gov record NCT05908084, source copy `cardio:ctgov-nct05908084-2026-06-26`, retrieved 2026-10-26)
- Started: 2023-09-07 (actual) (ClinicalTrials.gov record NCT05908084, source copy `cardio:ctgov-nct05908084-2026-06-26`, retrieved 2026-10-26)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT05908084, source copy `cardio:ctgov-nct05908084-2026-06-26`, retrieved 2026-10-26)
- Completion: 2028-06 (anticipated) (ClinicalTrials.gov record NCT05908084, source copy `cardio:ctgov-nct05908084-2026-06-26`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05908084, source copy `cardio:ctgov-nct05908084-2026-06-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05908084-2026-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
- Condition: End Stage Renal Disease (ESRD)
- Intervention (Biological): Acellular Tissue Engineered Vessel (ATEV)
- Intervention (Other): AVF
- Lead sponsor: Humacyte, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: IQVIA Biotech
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Humacyte, Inc. (`cardio:org-humacyte-inc`)
- Registry lists this organization as a collaborator: IQVIA Biotech (`cardio:org-iqvia-biotech`)

## Provenance

Content hash: b02f191bea93f7ad3c16133f71dd4bbb63c2e5bf119a8e5d442da29eacc19adc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
